Skip to main content

Table 4 Cell cycle distribution of MHCC97H cells after different drug treatments

From: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

 

G1 phase (%)/ p-value (vs. control)

S phase (%)/ p-value (vs. control)

G2/M phase (%)/ p-value (vs. control)

Control

47.53 ± 0.06

40.97 ± 0.15

11.50 ± 0.20

S

63.03 ± 0.95/p = 0.000

17.43 ± 0.85/p = 0.000

19.50 ± 0.10/p = 0.000

F

62.60 ± 0.70/p = 0.000

25.23 ± 0.72/p = 0.000

12.17 ± 1.95/p = 0.367

(S + F)

60.50 ± 0.50/p = 0.000

22.00 ± 0.10/p = 0.000

17.47 ± 0.35/p = 0.000

S + F

66.70 ± 0.30/p = 0.000

12.27 ± 0.45/p = 0.000

21.03 ± 0.75/p = 0.000

F + S

64.30 ± 1.10/p = 0.000

32.80 ± 1.00/p = 0.000

2.91 ± 0.07/p = 0.000

  1. S: sorafenib, F: 5-FU.